申请人:Harada Naoyuki
公开号:US20080076769A1
公开(公告)日:2008-03-27
Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2).
[wherein X is —CH
2
—, —O—, —S— or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R
1
and R
2
are (i) each is hydrogen or lower alkyl; (ii) R
1
and R
2
are combined to form lower alkylene; or (iii) R
1
is hydrogen or lower alkyl and R
2
is combined with R
4
or R
6
to form lower alkylene;
R
3
and R
4
are (i) each is hydrogen or lower alkyl; (ii) R
3
and R
4
are combined to form lower alkylene; or (iii) R
3
is hydrogen or lower alkyl and R
4
is combined with R
2
or R
6
to form lower alkylene;
R is
or —OR
7
;
R
5
and R
6
are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R
5
and R
6
are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R
5
is optionally substituted lower alkyl or hydrogen and R
6
is combined with R
2
or R
4
to form lower alkylene; R
7
is lower alkyl.
Norvaline衍生物的化学式[I]或其药学上可接受的盐,制备方法,含有该化合物的药物组合物,以及用于抑制甘氨酸转运体2型(GlyT2)的转运活性的用途。[其中X为-CH2-,-O-,-S-或单键;Ar为可选取代芳基或较低的环烷基;n为0至2;R1和R2为(i)氢或较低的烷基;(ii)R1和R2结合形成较低的烷基;或(iii)R1为氢或较低的烷基,R2与R4或R6结合形成较低的烷基;R3和R4为(i)氢或较低的烷基;(ii)R3和R4结合形成较低的烷基;或(iii)R3为氢或较低的烷基,R4与R2或R6结合形成较低的烷基;R为-OH或-OR7;R5和R6为(i)可选取代的较低烷基或氢;(ii)R5和R6结合形成脂肪族5-至6-成员杂环基;或(iii)R5为可选取代的较低烷基或氢,R6与R2或R4结合形成较低的烷基;R7为较低烷基。